ERBB2 is altered in 2.89% of intrahepatic cholangiocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for intrahepatic cholangiocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGF19 is altered in 2.8% of intrahepatic cholangiocarcinoma patients [2].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 0.55% of intrahepatic cholangiocarcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is altered in 16.88% of intrahepatic cholangiocarcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 4 clinical trials for intrahepatic cholangiocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

FGFR3 is altered in 2.02% of intrahepatic cholangiocarcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR4 is altered in 1.31% of intrahepatic cholangiocarcinoma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 is altered in 22.64% of intrahepatic cholangiocarcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].